Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Entrectinib exhibits activity in children with solid tumors

Publish date:: May 23, 2019

Key clinical point: Entrectinib demonstrated antitumor activity in children and adolescents with recurrent or refractory solid tumors.

Major finding: Twelve patients responded to entrectinib, and all responders had fusions or mutations in target genes – NTRK1/2/3 (TRKA/B/C), ROS1, or ALK.

Study details: Ongoing phase 1/1b trial of 29 patients.

Disclosures: The trial is sponsored by Hoffman-La Roche Ltd and supported by Alex’s Lemonade Stand Center of Excellence. The presenter has relationships with Lilly, Genentech/Roche, and Novartis.

Citation:

Robinson GW et al. ASCO 2019. Abstract 10009.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in CNS/Brain Cancer

Dexamethasone may ‘jeopardize’ benefit of immunotherapy in glioblastoma,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,

Immunotherapy could fill unmet need in leptomeningeal metastases,

Molecular features of medulloblastoma may help personalize radiotherapy,

‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients,